Triamcinolone acetonide suppresses inflammation and facilitates vascular barrier function in human retinal microvascular endothelial cells

Current Neurovascular Research

Volumn 14, Issue 3, 2017, Pages 232-241

  Imai, Shunsuke ^a   Otsuka, Tomohiro ^a   Naito, Akira ^a   Shimazawa, Masamitsu ^b   Hara, Hideaki ^b  

^a Wakamoto Pharmaceutical Co   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Anti VEGF; Diabetic macular edema; Glucocorticoid receptor; Inflammation; Retinal vascular permeability; Tight junction; Triamcinolone acetonide

Indexed keywords

CLAUDIN 5; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1BETA; OCCLUDIN; PROTEIN ZO1; TANESPIMYCIN; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR; VASCULOTROPIN; ANTIBODY; ANTIINFLAMMATORY AGENT; BENZOQUINONE DERIVATIVE; ENZYME INHIBITOR; MACROCYCLIC LACTAM; TJP1 PROTEIN, HUMAN; VASCULOTROPIN A;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG MECHANISM; HRMEC CELL LINE (RETINAL); HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIGHT JUNCTION; UPREGULATION; CAPILLARY PERMEABILITY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; IMMUNOLOGY; METABOLISM; RETINA; TIME FACTOR;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES; BENZOQUINONES; CAPILLARY PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-1BETA; LACTAMS, MACROCYCLIC; RETINA; TIME FACTORS; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZONULA OCCLUDENS-1 PROTEIN;

EID: 85029648388     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/1567202614666170619081929     Document Type: Article

References (47)

1. Gustavsson C, Agardh C-D, Agardh E. Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol 2013; 91(5): 445-52.
2. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116(1): 73-9.
3. Beltramo E, Porta M. Pericyte loss in diabetic retinopathy: Mechanisms and consequences. Curr Med Chem 2013; 20(26): 3218-25.
4. Kohner EM, Patel V, Rassam SM. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995; 44(6): 603-7.
5. Kristinsson JK, Gottfredsdottir MS, Stefansson E. Retinal vessel dilatation and elongation precedes diabetic macular oedema. Br J Ophthalmol 1997; 81: 274-8.
6. Simo R, Villarroel M, Corraliza L, Hernandez C, Garcia-Ramirez M. The retinal pigment epithelium: Something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol 2010; 2010: 190724.
7. Xu HZ, Le YZ. Significance of outer blood-retina barrier breakdown in diabetes and ischemia. Invest Ophthalmol Vis Sci 2011; 52(5): 2160-4.
8. Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: A comparative, non-randomised study. Br J Ophthalmol 2005; 89(3): 321-6.
9. Stewart MW. The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes 2015; 8: 473-82.
10. Rahman AM, Madge SN, Billing K, et al. Craniofacial fibrous dysplasia: clinical characteristics and long-term outcomes. Eye (Lond). 2009; 23(12): 2175-81.
11. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; Macugen 1013 Study Group. A phase 2/3, multicenter, randomized, doublemasked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118(6): 1107-18.
12. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the pan-American collaborative retina study group at 6- month follow-up. Ophthalmology 2007; 114(4): 743-50.
13. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46(4): 1440-4.
14. Kim YH, Choi MY, Kim YS, et al. Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage. Life Sci 2007; 81(14): 1167-73.
15. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57(4): 1026-33.
16. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274(33): 23463-7.
17. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437: 497-504.
18. Garoon RB, Coffee RE, Jiang L, Weng CY, Carvounis PE. Adjunct intravitreous triamcinolone acetonide in the treatment of diabetic macular edema with anti-vegf agents. J Ophthalmol 2016; 2016: 5282470.
19. Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 2002; 16(2): 163-70.
20. Shin ES, Sorenson CM, Sheibani N. Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res 2014; 9(3): 362-73.
21. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin- 6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003; 110(9): 1690-6.
22. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000; 156(5): 1733-9.
23. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, et al. The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol 2007; 22(2): 75-9.
24. Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H. Anti-tumor necrosis factor alpha for retinal diseases: Current knowledge and future concepts. J Ophthalmic Vis Res 2012; 7(1): 39-44.
25. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal antiinflammatory drugs prevent early diabetic retinopathy via TNFalpha suppression. FASEB J 2002; 16(3): 438-40.
26. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 2012; 37(5): 416-20.
27. Liu Y, Biarnes Costa M, Gerhardinger C. IL-1β is upregulated in the diabetic retina and retinal vessels: Cell-specific effect of high glucose and IL-1β autostimulation. PLoS One 2012; 7(5): e36949.
28. Mao C, Yan H. Roles of elevated intravitreal IL-1β and IL-10 levels in proliferative diabetic retinopathy. Ind J Ophthalmol 2014; 62(6): 699-701.
29. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47(11): 5106-15.
30. Ma TY, Iwamoto GK, Hoa NT, et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NFkappa B activation. Am J Physiol Gastrointest Liver Physiol 2004; 286(3): G367-76.
31. Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 2007; 178(7): 4641-9.
32. Kimura K, Teranishi S, Nishida T. Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci 2009; 50(2): 597-603.
33. Clark PR, Kim RK, Pober JS, Kluger MS. Tumor necrosis factor disrupts claudin-5 endothelial tight junction barriers in two distinct NF-?B-dependent phases. PLoS One 2015; 10(3): e0120075.
34. Kiriakidis S, Andreakos E, Monaco C, et al. VEGF expression in human macrophages is NF-kappaB-dependent: Studies using adenoviruses expressing the endogenous NF-kappaB inhibitor Ikappa- Balpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 2003; 116(Pt 4): 665-74.
35. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994; 91(2): 752-6.
36. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS, Jr. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995; 15(2): 943-53.
37. Barnes PJ. Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci (Lond) 1998; 94(6): 557-72.
38. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell 1998; 93(4): 487-90.
39. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79(4): 376-84.
40. Romero IA, Radewicz K, Jubin E, et al. Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. Neurosci Lett 2003; 344(2): 112-6.
41. Forster C, Burek M, Romero IA, Weksler B, Couraud PO, Drenckhahn D. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human bloodbrain barrier. J Physiol 2008; 586(7): 1937-49.
42. Deissler HL, Deissler H, Lang GE. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: Similarities and differences. Br J Ophthalmol 2012; 96(7): 1023-8.
43. Furihata T, Kawamatsu S, Ito R, et al. Hydrocortisone enhances the barrier properties of HBMEC/ciβ, a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. Fluids Barriers CNS 2015; 12: 7.
44. Hsieh YT, Yang CM, Chang SH. Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. J Formos Med Assoc 2016; 0929-6646(16): 30256
45. Felinski EA, Cox AE, Phillips BE, Antonetti DA. Glucocorticoids induce transactivation of tight junction genes occludin and claudin- 5 in retinal endothelial cells via a novel cis-element. Exp Eye Res 2008; 86(6): 867-78.
46. Liang IC, Lin YR, Chien HW, Liu KR. Vision preservation in eyes of polypoidal choroidal vasculopathy with low-dose intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther 2017; 33(1): 42-9.
47. Kaplan RI, Chaugule SS, Finger PT. Intravitreal triamcinolone acetate for radiation maculopathy recalcitrant to high-dose intravitreal bevacizumab. Br J Ophthalmol 2017; 310315.